{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:15:42Z","timestamp":1792602942879,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-024-04112-8","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T15:54:19Z","timestamp":1732290859000},"page":"80-90","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database"],"prefix":"10.1007","volume":"88","author":[{"given":"Jianxing","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haobin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maobai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"issue":"2","key":"4112_CR1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S2468-1253(22)00338-7","volume":"8","author":"G Targher","year":"2023","unstructured":"G. Targher, A. Mantovani, C.D. Byrne, Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease. Lancet Gastroenterol. Hepatol. 8(2), 179\u2013191 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"10","key":"4112_CR2","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00125-023-05906-7","volume":"66","author":"DJ Drucker","year":"2023","unstructured":"D.J. Drucker, J.J. Holst, The expanding incretin universe: from basic biology to clinical translation. Diabetologia 66(10), 1765\u20131779 (2023).","journal-title":"Diabetologia"},{"issue":"8","key":"4112_CR3","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/apt.16794","volume":"55","author":"AS Barritt","year":"2022","unstructured":"A.S. Barritt, E. Marshman, M. Noureddin, Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know. Aliment Pharm. Ther. 55(8), 944\u2013959 (2022).","journal-title":"Aliment Pharm. Ther."},{"issue":"7","key":"4112_CR4","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","volume":"30","author":"HM Colhoun","year":"2024","unstructured":"H.M. Colhoun, I. Lingvay, P.M. Brown, J. Deanfield, K. Brown-Frandsen, S.E. Kahn et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat. Med. 30(7), 2058\u20132066 (2024).","journal-title":"Nat. Med."},{"key":"4112_CR5","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.2337\/dc24-0764","volume":"47","author":"I Lingvay","year":"2024","unstructured":"I. Lingvay, J. Deanfield, S.E. Kahn, P.E.Weeke, H. Toplak, B.M. Scirica et al. Semaglutide and cardiovascular outcomes by baseline HbA1c and change in HbA1c in people with overweight or obesity but without diabetes in SELECT. Diabetes Care 47, 1360\u20131369 (2024).","journal-title":"Diabetes Care"},{"issue":"10148","key":"4112_CR6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","volume":"392","author":"PM O\u2019Neil","year":"2018","unstructured":"P.M. O\u2019Neil, A.L. Birkenfeld, B. McGowan, O. Mosenzon, S.D. Pedersen, S. Wharton et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 392(10148), 637\u2013649 (2018).","journal-title":"Lancet"},{"issue":"8","key":"4112_CR7","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/s41366-023-01321-5","volume":"47","author":"B Tan","year":"2023","unstructured":"B. Tan, X.H. Pan, H.S.J. Chew, R.S.J. Goh, C. Lin, V.V. Anand et al. Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. Int J. Obes. (Lond.) 47(8), 677\u2013685 (2023).","journal-title":"Int J. Obes. (Lond.)"},{"key":"4112_CR8","doi-asserted-by":"crossref","first-page":"102661","DOI":"10.1016\/j.eclinm.2024.102661","volume":"73","author":"H Moll","year":"2024","unstructured":"H. Moll, E. Frey, P. Gerber, B. Geidl, M. Kaufmann, J. Braun et al. GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study. EClinicalMedicine 73, 102661 (2024).","journal-title":"EClinicalMedicine"},{"issue":"5","key":"4112_CR9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","volume":"182","author":"L He","year":"2022","unstructured":"L. He, J. Wang, F. Ping, N. Yang, J. Huang, Y. Li et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: A systematic review and meta-analysis of randomized clinical trials. JAMA Intern. Med. 182(5), 513\u2013519 (2022).","journal-title":"JAMA Intern. Med"},{"issue":"2","key":"4112_CR10","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc22-1148","volume":"46","author":"J Bezin","year":"2023","unstructured":"J. Bezin, A. Gouverneur, M. P\u00e9nichon, C. Mathieu, R. Garrel, D. Hillaire-Buys et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diab. Care 46(2), 384\u2013390 (2023).","journal-title":"Diab. Care"},{"issue":"6","key":"4112_CR11","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.survophthal.2023.07.002","volume":"68","author":"I Kapoor","year":"2023","unstructured":"I. Kapoor, S.M. Sarvepalli, D. D\u2019Alessio, D.S. Grewal, M. Hadziahmetovic, GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials. Surv. Ophthalmol. 68(6), 1071\u20131083 (2023).","journal-title":"Surv. Ophthalmol."},{"issue":"1","key":"4112_CR12","volume":"21","author":"D Zheng","year":"2023","unstructured":"D. Zheng, N. Li, R. Hou, X. Zhang, L. Wu, J. Sundquist et al. Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies. BMC Med. 21(1), 40 (2023).","journal-title":"BMC Med"},{"issue":"12","key":"4112_CR13","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.4103\/ijo.IJO_1240_18","volume":"66","author":"DJ Browning","year":"2018","unstructured":"D.J. Browning, M.W. Stewart, C. Lee, Diabetic macular edema: Evidence-based management. Indian J. Ophthalmol. 66(12), 1736\u20131750 (2018).","journal-title":"Indian J. Ophthalmol."},{"key":"4112_CR14","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","volume":"142","author":"JT Hathaway","year":"2024","unstructured":"J.T. Hathaway, M.P. Shah, D.B. Hathaway, S.M. Zekavat, D. Krasniqi, J.W. Gittinger et al. Risk of nonarteritic anteriorischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol 142, 732\u2013739 (2024).","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"4112_CR15","volume":"22","author":"J Zhou","year":"2024","unstructured":"J. Zhou, Y. Zheng, B. Xu, S. Long, L.E. Zhu, Y. Liu et al. Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database. BMC Med. 22(1), 65 (2024).","journal-title":"BMC Med."},{"key":"4112_CR16","first-page":"7882277","volume":"2022","author":"W Ren","year":"2022","unstructured":"W. Ren, W. Wang, Y. Guo, Analysis of adverse reactions of aspirin in prophylaxis medication based on FAERS database. Comput Math. Methods Med. 2022, 7882277 (2022).","journal-title":"Comput Math. Methods Med."},{"issue":"2","key":"4112_CR17","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","volume":"9","author":"RJ Yu","year":"2021","unstructured":"R.J. Yu, M.S. Krantz, E.J. Phillips, C.A. Stone, Emerging causes of drug-induced anaphylaxis: A review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS). J. Allergy Clin. Immunol. Pract. 9(2), 819\u2013829.e2 (2021).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"4112_CR18","first-page":"3695101","volume":"2020","author":"Y Hu","year":"2020","unstructured":"Y. Hu, Z. Bai, Y. Tang, R. Liu, B. Zhao, J. Gong et al. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: A pharmacovigilance study with data from the U.S. FDA adverse event reporting system. J. Diab. Res. 2020, 3695101 (2020).","journal-title":"J. Diab. Res."},{"key":"4112_CR19","doi-asserted-by":"crossref","first-page":"1043789","DOI":"10.3389\/fendo.2022.1043789","volume":"13","author":"L Liu","year":"2022","unstructured":"L. Liu, J. Chen, L. Wang, C. Chen, L. Chen, Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol. (Lausanne) 13, 1043789 (2022).","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"2","key":"4112_CR20","doi-asserted-by":"crossref","first-page":"166","DOI":"10.7326\/M22-2453","volume":"176","author":"RB Melles","year":"2023","unstructured":"R.B. Melles, A.M. Jorge, M.F. Marmor, B. Zhou, C. Conell, J. Niu et al. Hydroxychloroquine dose and risk for incident retinopathy : A cohort study. Ann. Intern Med. 176(2), 166\u2013173 (2023).","journal-title":"Ann. Intern Med."},{"issue":"1","key":"4112_CR21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"E.P. van Puijenbroek, A. Bate, H.G.M. Leufkens, M. Lindquist, R. Orre, A.C.G. Egberts, A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 11(1), 3\u201310 (2002).","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"1","key":"4112_CR22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"G.N. Nor\u00e9n, J. Hopstadius, A. Bate, Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat. Methods Med. Res. 22(1), 57\u201369 (2013).","journal-title":"Stat. Methods Med. Res."},{"issue":"1","key":"4112_CR23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/cpt.2920","volume":"114","author":"S Xia","year":"2023","unstructured":"S. Xia, H. Gong, Y. Zhao, L. Guo, Y. Wang, R. Ma et al. Tumor lysis syndrome associated with monoclonal antibodies in patients with multiple myeloma: A pharmacovigilance study based on the FAERS database. Clin. Pharm. Ther. 114(1), 211\u2013219 (2023).","journal-title":"Clin. Pharm. Ther."},{"issue":"5","key":"4112_CR24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11095-020-02801-3","volume":"37","author":"Y Noguchi","year":"2020","unstructured":"Y. Noguchi, T. Tachi, H. Teramachi, Comparison of signal detection algorithms based on frequency statistical model for drug-drug interaction using spontaneous reporting systems. Pharm. Res. 37(5), 86 (2020).","journal-title":"Pharm. Res."},{"issue":"10","key":"4112_CR25","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","volume":"36","author":"O Sauzet","year":"2013","unstructured":"O. Sauzet, A. Carvajal, A. Escudero, M. Molokhia, V.R. Cornelius, Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf. 36(10), 995\u20131006 (2013).","journal-title":"Drug Saf."},{"issue":"10","key":"4112_CR26","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","volume":"4","author":"E von Elm","year":"2007","unstructured":"E. von Elm, D.G. Altman, M. Egger, S.J. Pocock, P.C. G\u00f8tzsche, J.P. Vandenbroucke et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 4(10), e296 (2007).","journal-title":"PLoS Med."},{"issue":"19","key":"4112_CR27","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"S.P. Marso, S.C. Bain, A. Consoli, F.G. Eliaschewitz, E. J\u00f3dar, L.A. Leiter et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375(19), 1834\u20131844 (2016).","journal-title":"N. Engl. J. Med."},{"issue":"10193","key":"4112_CR28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"H.C. Gerstein, H.M. Colhoun, G.R. Dagenais, R. Diaz, M. Lakshmanan, P. Pais et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193), 121\u2013130 (2019).","journal-title":"Lancet"},{"key":"4112_CR29","doi-asserted-by":"crossref","unstructured":"J.E. Blau, S.H. Tella, S.I. Taylor, K.I. Rother. Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data. Diabetes Metab. Res. Rev. 2017;33(8).","DOI":"10.1002\/dmrr.2924"},{"issue":"4","key":"4112_CR30","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/dom.13172","volume":"20","author":"T Vilsb\u00f8ll","year":"2018","unstructured":"T. Vilsb\u00f8ll, S.C. Bain, L.A. Leiter, I. Lingvay, D. Matthews, R. Sim\u00f3 et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diab. Obes. Metab. 20(4), 889\u2013897 (2018).","journal-title":"Diab. Obes. Metab."},{"issue":"1","key":"4112_CR31","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2337\/dc20-1815","volume":"44","author":"MA Bethel","year":"2021","unstructured":"M.A. Bethel, R. Diaz, N. Castellana, I. Bhattacharya, H.C. Gerstein, M.C. Lakshmanan, HbA1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: A meta-analysis and meta-regression. Diab. Care 44(1), 290\u2013296 (2021).","journal-title":"Diab. Care"},{"issue":"7","key":"4112_CR32","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"T. Sakaeda, A. Tamon, K. Kadoyama, Y. Okuno, Data mining of the public version of the FDA adverse event reporting system. Int J. Med. Sci. 10(7), 796\u2013803 (2013).","journal-title":"Int J. Med. Sci."},{"issue":"3","key":"4112_CR33","first-page":"420","volume":"10","author":"MA Khaleel","year":"2022","unstructured":"M.A. Khaleel, A.H. Khan, S.M.S. Ghadzi, A.S. Adnan, Q.M. Abdallah, A standardized dataset of a spontaneous adverse event reporting system. Healthc. (Basel) 10(3), 420 (2022).","journal-title":"Healthc. (Basel)"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-04112-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-04112-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-04112-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T03:52:03Z","timestamp":1742788323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-04112-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["4112"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-04112-8","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,22]]},"assertion":[{"value":"27 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}